In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding

February 24, 2026 - 17:24

During a recent quarterly earnings discussion, the CEO of Hims & Hers, Andrew Dudum, directly confronted the growing regulatory and media attention surrounding compounded versions of popular GLP-1 weight loss medications. Dudum acknowledged the environment of increased scrutiny but emphasized the company's commitment to its established protocols.

The executive outlined the company's approach, stating their healthcare providers prescribe compounded medications only when deemed medically appropriate and in full compliance with regulations. He stressed that patient safety and clear communication are paramount, with the company ensuring customers understand the nature and sourcing of their treatments.

While acknowledging that the public debate has impacted some consumer sentiment, Dudum expressed confidence in the business model. He pointed to strong demand for the company's broader suite of telehealth services beyond weight management as a stabilizing factor. The leadership remains focused on growth, betting that transparency and clinical rigor will sustain consumer trust despite the challenging headlines surrounding the fast-evolving weight loss drug sector. The company's financial performance continues to be watched closely as the market for these sought-after treatments develops.